A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/2006
08/22/2006	US7094424 Cationic lipid compositions targeting angiogenic endothelial cells
08/22/2006	US7094410 DNA vaccine against proliferating endothelial cells and methods of use thereof
08/22/2006	US7094409 Antigen arrays for treatment of allergic eosinophilic diseases
08/22/2006	CA2368138C Mechanically stable pharmaceutical presentation form containing liquid or semisolid surface-active substances
08/17/2006	WO2006086716A2 Donor lymphocyte infusion of activated t cells for the treatment of cancer
08/17/2006	WO2006086600A1 Proteasome inhibitors and methods of using the same
08/17/2006	WO2006086539A1 Pyridopyrazolopyrimidine compounds and their uses as anti-cancer and anti-diabete drugs
08/17/2006	WO2006086484A1 Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
08/17/2006	WO2006086172A1 Cci-779 polymorph and use thereof
08/17/2006	WO2006085828A1 Methods for the detection of hepatocellular carcinoma
08/17/2006	WO2006085689A1 Anticancer agent to be combined with telomelysin
08/17/2006	WO2006085688A1 Psychogenic pain therapeutic agent
08/17/2006	WO2006085607A1 Plant component-containing emulsion preparation and method for producing the same
08/17/2006	WO2006085553A1 Anti-tlr6 antibody and utilization of the same
08/17/2006	WO2006085517A1 Ointment preparation or suppository for pdt based on chlorin or porphyrin derivative
08/17/2006	WO2006085411A1 Novel adjuvant for evoking immune responce and utilization of the same
08/17/2006	WO2006085219A2 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy
08/17/2006	WO2006084996A1 Substituted pyrroles, compositions containing same, method for making same and use thereof
08/17/2006	WO2006084904A1 Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
08/17/2006	WO2006084869A1 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
08/17/2006	WO2006084338A1 Novel tubulin polymerisation inhibitors
08/17/2006	WO2006084337A1 A molecule and chimeric molecules thereof
08/17/2006	WO2006084327A1 A molecule and chimeric molecules thereof
08/17/2006	WO2006068975A3 Binding proteins specific for human matriptase
08/17/2006	WO2006067311A3 Cdc25 phosphatase inhibitors
08/17/2006	WO2006065780A3 Combinations of therapeutic agents for treating cancer
08/17/2006	WO2006055621A3 Histone deacetylase inhibitors and methods of use
08/17/2006	WO2006052976A3 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
08/17/2006	WO2006042173A3 Modulators of hepatocyte growth factor activator
08/17/2006	WO2006002383A3 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents
08/17/2006	WO2005115363A3 Method for treating skeletal disorders resulting from fgfr malfunction
08/17/2006	WO2005106039A8 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
08/17/2006	WO2005097140A3 Selective antagonists of a2a adenosine receptors
08/17/2006	US20060184074 Solid hydrogel coupling for ultrasound imaging and therapy
08/17/2006	US20060183931 Multi-substituted selective androgen receptor modulators and methods of use thereof
08/17/2006	US20060183805 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
08/17/2006	US20060183798 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
08/17/2006	US20060183794 Drug composition containing nf-kb inhibitor
08/17/2006	US20060183784 Human growth hormone antagonists
08/17/2006	US20060183782 3-[5-(4-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]-N-(4-sulfamoylphenyl)-propionamide; compounds are protein tyrosine phosphatse inhibitors; antiinflmmatory, anticarcinogenic agents
08/17/2006	US20060183774 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
08/17/2006	US20060183770 Sulfonamide derivative having isoxazole ring
08/17/2006	US20060183765 Methods of treating cancer using an FPT inhibitor and antineoplastic agents
08/17/2006	US20060183760 (2S3R)-3-{9-Isopropyl-6-[(pyridin-2-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative; cancer, leukemia, psoriasis; cyclin-dependent kinase (CDK) inhibitors
08/17/2006	US20060183755 Tyrosine kinase inhibitors
08/17/2006	US20060183749 Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
08/17/2006	US20060183739 Carbonyl compounds
08/17/2006	US20060183728 Combination chemotherapy compositions and methods
08/17/2006	US20060183713 Compositions of low molecular weight heparin produced with modified heparinase III
08/17/2006	US20060183687 Novel therapeutic molecules
08/17/2006	US20060183664 Pharmaceutical composition for delayed hypersensitivity
08/17/2006	US20060183229 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
08/17/2006	US20060183186 Gene expression profiles in stomach cancer
08/17/2006	US20060183105 Human brain-derived tissue-specific potassium channel
08/17/2006	US20060182809 System for transporting active substances in a biological system
08/17/2006	US20060182807 Copolymer and hemoprotein based novel compounds and uses thereof
08/17/2006	US20060182760 Method for protecting living body from external factor and composition therefor
08/17/2006	US20060182741 Use of adcc-optimized antibodies for treating weak patients
08/17/2006	US20060182740 Buffered formulations for concentrating antibodies and methods of use thereof
08/17/2006	US20060182734 Contacting polysaccharide with disaccharide repeat unit of uronic acid [ alpha -L-iduronic acid or beta -D-glucuronic acid ] linked 1, 4 to alpha -D-hexosamine with mutant heparinase III; sequencing mucopolysaccharides; antitumor, anticarcinogenic and antimetastasis agents; angiogenesis inhibitors
08/17/2006	US20060182718 Methods and compositions comprising DNA damaging agents and p53
08/17/2006	US20060182684 non-invasive and flexible method and carrier for drug delivery across the blood-brain barrier; brain tumors, brain metastases, stroke, schizophrenia, epilepsy, Alzheimer's, Parkinson's and Huntington's disease
08/17/2006	US20060182683 Methods for reduced renal uptake of protein conjugates
08/17/2006	CA2599611A1 Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
08/17/2006	CA2597447A1 Novel tubulin polymerisation inhibitors
08/17/2006	CA2597346A1 A molecule and chimeric molecules thereof
08/17/2006	CA2597273A1 Proteasome inhibitors and methods of using the same
08/17/2006	CA2596822A1 Substituted pyrroles, compositions containing same, method for making same and use thereof
08/17/2006	CA2596501A1 Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
08/17/2006	CA2596422A1 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy
08/17/2006	CA2596202A1 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
08/17/2006	CA2595766A1 Cci-779 polymorph and use thereof
08/17/2006	CA2595526A1 Colonic delivery of active agents
08/17/2006	CA2595395A1 Inhibiting her2 shedding with matrix metalloprotease antagonists
08/16/2006	EP1690937A1 Method of constructing transgenic dendritic cell
08/16/2006	EP1690864A2 Tricyclic purine compounds and their analogs as inhibitors of cytokine signalling
08/16/2006	EP1690853A1 W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
08/16/2006	EP1690852A1 Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
08/16/2006	EP1690542A2 Pharmaceutical composition for the treatment of ovarian cancer
08/16/2006	EP1690538A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
08/16/2006	EP1689846A2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
08/16/2006	EP1689745A1 Novel macrocycles for treating tumor diseases
08/16/2006	EP1689739A1 Azole-based kinase inhibitors
08/16/2006	EP1689730A1 Gsk-3 inhibitors isolated from marine organisms
08/16/2006	EP1689724A1 Quinazolinone compounds as anticancer agents
08/16/2006	EP1689722A2 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
08/16/2006	EP1689719A1 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
08/16/2006	EP1689717A1 Substituted isoquinolines useful in the treatment of diseases such as cancer and atherosclerosis
08/16/2006	EP1689442A2 Composition comprising antibodies and methods of using the same for targeted nanoparticulate active agent delivery
08/16/2006	EP1689435A1 Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
08/16/2006	EP1689429A1 Biomarkers for the efficacy of somatostatin analogue treatment
08/16/2006	EP1689424A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
08/16/2006	EP1689413A2 Glycerophospholipids containing omega-3 and omega-6 fatty acids
08/16/2006	EP1689406A2 Heterocyclic inhibitors of mek and methods of use thereof
08/16/2006	EP1689405A1 Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
08/16/2006	EP1689404A1 Combination
08/16/2006	EP1689403A2 Heteroaryl-hydrazone compounds
08/16/2006	EP1689402A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
08/16/2006	EP1689400A2 Novel compound, corresponding compositions, preparation and/or treatment methods
08/16/2006	EP1689395A2 Vinca derivatives

1 ... 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 ... 2211